Longeveron Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Stephen H. Willard
- Full Time Employees
- 25
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1951 NW 7th Avenue Miami FL United States of America 33136
- IPO Date
- Feb 12, 2021
- CIK
- 0001721484
- Website
- longeveron.com
- Similar Companies
- Business
- Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage regenerative medicine biotechnology company that develops cellular therapies derived from culture-expanded mesenchymal stem cells (MSCs) sourced from bone marrow of young healthy adult donors for life-threatening and chronic aging-related conditions; its lead investigational product, laromestrocel (Lomecel-B™), targets hypoplastic left heart syndrome (HLHS) in a Phase 2b pivotal trial (ELPIS II) with top-line results expected in Q3 2026, Alzheimer's disease following completion of Phase 2a (CLEAR MIND) and positive FDA Type B meeting in March 2025 for a proposed Phase 2/3 trial, aging frailty after Phase 2 completion, and pediatric dilated cardiomyopathy with a planned Phase 2 pivotal trial in 2026; the company also generates revenue from clinical trial services and contract manufacturing. Founded in 2014 and headquartered at 1951 NW 7th Avenue, Suite 520, Life Science & Technology Park, Miami, Florida, Longeveron operates primarily in the United States with additional activities in Japan for aging frailty trials and pursues global partnerships, including with the Alzheimer's Association. Recent developments include closing an up to $17.5 million public offering in August 2025 to fund laromestrocel programs and extend runway, appointing Wa'el Hashad as Chief Executive Officer effective March 2023, and receiving Rare Pediatric Disease Designation from the FDA for HLHS with plans for a Biologics License Application submission by late 2026.
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
Longeveron Inc. (LGVN) Q1 2026 Earnings Call Transcript
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
Reviewing Longeveron (NASDAQ:LGVN) & Voyager Therapeutics (NASDAQ:VYGR)
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
Longeveron Braces For Q4 Results Following Recent Funding Boost
Longeveron Announces Closing of Private Placement of up to $30 Million
Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)